Indaptus Therapeutics Q3 net loss narrows as R&D costs fall

By Reuters News


Overview

  • US biotechnology firm's Q3 net loss narrowed sharply from prior year

  • Research and development expenses fell 82% due to lower clinical costs and reduced headcount

  • Company completed $24 mln private placement to fund research and working capital


Outlook

  • Company intends to use recent funding for R&D and early-stage neurotechnology device research

  • Indaptus expects current liquidity to fund anticipated operating and capital expenditures


Result Drivers

  • R&D COST CUTS - Research and development expenses fell sharply due to lower clinical costs from Decoy20 Phase 1 study wind-down and reduced headcount

  • ADMINISTRATIVE SAVINGS - General and administrative expenses declined due to lower management transition costs and payroll reductions

  • LIQUIDITY - As of September 30, the company had $26.6 million in cash and cash equivalents and $4.0 million in short-term investments


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Net Loss Per Share

$0.01


Reuters Recommended Reads

  • Nov 12 - MDxHealth's Q3 revenue misses expectations due to disrupted commercial execution

  • Nov 12 - Rocket Pharmaceuticals Q3 net loss narrows as R&D costs fall

  • Nov 13 - PDS Biotechnology Q3 net loss narrows on lower R&D costs


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk